Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Cross-protective immunity following coronavirus vaccination and coronavirus infection
Tanushree Dangi, … , Justin M. Richner, Pablo Penaloza-MacMaster
Tanushree Dangi, … , Justin M. Richner, Pablo Penaloza-MacMaster
Published October 8, 2021
Citation Information: J Clin Invest. 2021;131(24):e151969. https://doi.org/10.1172/JCI151969.
View: Text | PDF
Research Article COVID-19 Vaccines

Cross-protective immunity following coronavirus vaccination and coronavirus infection

  • Text
  • PDF
Abstract

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have shown efficacy against SARS-CoV-2, it is unknown if coronavirus vaccines can also protect against other coronaviruses that may infect humans in the future. Here, we show that coronavirus vaccines elicited cross-protective immune responses against heterologous coronaviruses. In particular, we show that a severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) vaccine developed in 2004 and known to protect against SARS-CoV-1 conferred robust heterologous protection against SARS-CoV-2 in mice. Similarly, prior coronavirus infections conferred heterologous protection against distinct coronaviruses. Cross-reactive immunity was also reported in patients with coronavirus disease 2019 (COVID-19) and in individuals who received SARS-CoV-2 vaccines, and transfer of plasma from these individuals into mice improved protection against coronavirus challenges. These findings provide the first demonstration to our knowledge that coronavirus vaccines (and prior coronavirus infections) can confer broad protection against heterologous coronaviruses and establish a rationale for universal coronavirus vaccines.

Authors

Tanushree Dangi, Nicole Palacio, Sarah Sanchez, Mincheol Park, Jacob Class, Lavanya Visvabharathy, Thomas Ciucci, Igor J. Koralnik, Justin M. Richner, Pablo Penaloza-MacMaster

×

Figure 5

Cross-protective immunity following coronavirus vaccination or coronavirus infection.

Options: View larger image (or click on image) Download as PowerPoint
Cross-protective immunity following coronavirus vaccination or coronavir...
(A) Viral loads after SARS-CoV-2 (MA10) challenge in SARS-CoV-1–vaccinated mice. LOD = 0.007 genomes/g. (B) Viral loads after OC43 challenge in SARS-CoV-2–vaccinated mice. LOD = 27 genomes/g. (C) Viral loads after MHV-1 challenge in OC43-immune mice. (D) Viral loads after MHV-A59 challenge in MHV-1–immune mice. In A–D, mice were intramuscularly primed and boosted after 3 weeks (see Methods). Mice were challenged intranasally 2 weeks after the boost. (E) Viral loads after OC43 challenge in mice that received 50 μL human plasma (before or after vaccination). Plasma was adoptively transferred into naive mice, and on day 1 after transfer, mice were challenged intranasally with OC43. OC43 IgG titers before vaccination (V0) ranged from 12,150 to 109,350, and after vaccination (V1), they ranged from 328,050 to 984,150. (F) OC43 PRNT in plasma before and after vaccination. (G) Viral loads after OC43 challenge in mice that received 50 μL human plasma (pre-2019 vs. COVID-19). Plasma was adoptively transferred into naive mice, and on day 1 after transfer, mice were challenged intranasally with OC43. OC43 IgG titers were 4050 for all pre-2019 samples and 63,450 for all COVID-19 samples. (H) OC43 PRNT in plasma from pre-2019 donors and patients with COVID-19. Lung viral loads were quantified by RT-PCR (A, B, E, and G) or plaque assays (C, D, F, and H). Data are from day 5 after challenge unless otherwise indicated. Dashed lines represent the LOD. A–D data are from 2 independent experiments with 3–5 mice/group. Data in E–H are from 1 experiment with 5 mice/group. Data from all experiments are shown. In A–D, F, and H, error bars indicate the SEM. Panels E and G show paired values. Values below the LOD in log scales represent zero values. *P < 0.05, **P < 0.01, and ***P < 0.001, by nonparametric Mann-Whitney U test (A–D, F, and H) and paired t test (E and G).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts